AbbVie says Skyrizi maintains strong sales momentum as competition rises

AbbVie highlighted that its immunology drug Skyrizi continues to generate robust sales despite increasing competition in the market. The company noted that demand for the therapy remains solid and that it is performing well against newer entrants.

In response to the competitive pressure, AbbVie raised its full‑year sales guidance, indicating confidence in the product's ongoing performance. Executives emphasized that the drug's efficacy and patient uptake support the optimistic outlook.

Analysts had earlier expressed concerns about how Skyrizi would fare against rival offerings, but the latest guidance suggests the drug is holding its position in the market.

The company’s messaging underscores a focus on sustaining growth for its immunology portfolio while navigating a more crowded therapeutic landscape.